(Q37649251)

21 August 2017

1 reference

title

Peripheral blood stem cell mobilization tactics (English)

1 reference

21 August 2017

Lindsay L Rosenbeck

1

1 reference

21 August 2017

Shivani Srivastava

series ordinal

2

1 reference

21 August 2017

Patrick J Kiel

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

Annals of Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

44

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

107-116

1 reference

Hematopoietic stem-cell transplantation

21 August 2017

cites work

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials

21 January 2018

1 reference

High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells

21 January 2018

1 reference

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy

21 January 2018

1 reference

21 January 2018

1 reference

The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice

21 January 2018

1 reference

Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells

21 January 2018

1 reference

Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma

21 January 2018

1 reference

The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.

21 January 2018

1 reference

Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide

21 January 2018

1 reference

Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor.

21 January 2018

1 reference

Management strategies for the hard-to-mobilize patient

21 January 2018

1 reference

The whys and hows of hematopoietic progenitor and stem cell mobilization

21 January 2018

1 reference

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

21 January 2018

1 reference

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma

21 January 2018

1 reference

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

21 January 2018

1 reference

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

21 January 2018

1 reference

An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors

21 January 2018

1 reference

Lineage-specific hematopoietic growth factors

21 January 2018

1 reference

Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells

21 January 2018

1 reference

Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.

21 January 2018

1 reference

Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.

21 January 2018

1 reference

Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells

21 January 2018

1 reference

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

21 January 2018

1 reference

ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

21 January 2018

1 reference

ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.

21 January 2018

1 reference

Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.

21 January 2018

1 reference

Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.

21 January 2018

1 reference

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma

21 January 2018

1 reference

Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.

21 January 2018

1 reference

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

21 January 2018

1 reference

Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers

21 January 2018

1 reference

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

21 January 2018

1 reference

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

21 January 2018

1 reference

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

21 January 2018

1 reference

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

21 January 2018

1 reference

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

21 January 2018

1 reference

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

21 January 2018

1 reference

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M289

1 reference

21 August 2017

1 reference